Benefits
Diuretic for kidney/urinary conditions
Clinical studies report Polyporus umbellatus is an effective diuretic for pyelonephritis, nephritis, and urolithiasis, without notable side effects. Foundational Chinese clinical evidence supporting the traditional diuretic indication, though older by modern methodological standards.
Chronic hepatitis B (9-RCT systematic review, 936 patients)
A systematic review of 9 RCTs (936 patients) reported PUPS positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19) in chronic hepatitis B. Overall evidence quality is rated low — rigorous double-blind placebo-controlled trials are still needed.
Xiong 1993 chronic HBV combination RCT
A randomized trial compared Dan Shen + PUPS vs each alone in chronic HBV. Combination context — most clinical evidence is in TCM combination formulas rather than isolated PUPS.
Anti-aldosteronic diuretic mechanism (ergone)
Ergone has anti-aldosteronic diuretic activity by blocking aldosterone (the sodium/potassium-regulating mineralocorticoid). A distinguishing mechanism vs osmotic or loop diuretics, and the biochemically interesting basis for the traditional diuretic action.
Antitumor polysaccharide (Wu 1997)
PUPS inhibits cachexia induced by toxohormone-L. An anti-cachexic polysaccharide mechanism with potential relevance to integrative oncology applications, though human cancer-prevention or adjunct evidence remains limited.
Antioxidant triterpenes
Zhuling protected red blood cells from AAPH-induced hemolysis (50-1000 µg/mL dose-dependent). Polyporusterones A and B are free radical scavengers; polyporusterone B is significantly stronger than A. 150 mg ingestion increased plasma free-radical scavenging in rats.
Renal fibrosis protection
Preclinical evidence that Polyporus umbellatus protects against renal fibrosis by regulating intrarenal fatty acyl metabolites. Mechanistic finding pending clinical translation in chronic kidney disease populations.
Mechanism of action
Anti-aldosteronic diuretic activity (ergone)
Ergone blocks aldosterone, the mineralocorticoid hormone regulating sodium and potassium. Distinguishing pharmacology from osmotic or loop diuretics; mechanistically resembles spironolactone-class diuretics at the receptor level.
PUPS β-glucan immunomodulation
PUPS — β-glucan with (1-3) backbone and (1-6) side chains, MW ~1.6×10⁵ Da — binds Dectin-1 receptors on innate immune cells. Foundational mushroom β-glucan immunomodulation pathway.
Polyporusterone A and B antioxidant triterpenes
Triterpene carboxylic acids with free radical scavenging activity. Polyporusterone B is significantly more potent than A, with demonstrated dose-dependent protection of red blood cells from AAPH-induced hemolysis.
Anti-cachexic polysaccharide
PUPS inhibits cachexia induced by toxohormone-L. Polysaccharide-based mechanism distinct from the small-molecule activities of ergone or polyporusterones.
Renal fibrosis protection (preclinical)
Protection against renal fibrosis via regulation of intrarenal fatty acyl metabolites. Lipid-metabolism mechanism in animal models; not yet translated to clinical CKD endpoints.
Radio- and chemoprotective effects
Polyporus extracts have shown radio- and chemoprotective effects in human cultured cells and mice. Mechanistic basis for the integrative-oncology adjunct positioning.
Clinical trials
Clinical studies confirmed Polyporus umbellatus is an effective diuretic for pyelonephritis, nephritis, and urolithiasis without notable side effects.
Clinical population described in trial publication.
Clinical studies confirmed Polyporus umbellatus is an effective diuretic for pyelonephritis, nephritis, and urolithiasis without notable side effects. Foundational Chinese clinical evidence; older methodology by modern standards but consistent with traditional use record.
Evidence review of 9 clinical trials (n=936) — PUPS showed positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19).
9 clinical trials pooled
Evidence review of 9 clinical trials (n=936) — PUPS showed positive HBeAg clearance vs placebo (RR 3.06, 95% CI 1.13-8.29) and HBV DNA clearance vs non-specific treatment (RR 4.14, 95% CI 1.00-17.19). Critical limitation acknowledged in the review itself: overall evidence quality is low, with rigorous double-blind placebo-controlled trials still needed.
Zhongguo Zhong Xi Yi Jie He Za Zhi 13:533-535 — 90-patient clinical trial comparing Dan Shen + PUPS vs each component alone in chronic HBV.
Clinical population described in trial publication.
Zhongguo Zhong Xi Yi Jie He Za Zhi 13:533-535 — 90-patient clinical trial comparing Dan Shen + PUPS vs each component alone in chronic HBV. Most Polyporus clinical evidence is in TCM combination formulas (Wuling San, Si Ling San, Dan Shen + PUPS) rather than isolated PUPS.